The aCCP assay on the IMMULITE® 2000 XPi has good performance characteristics and shows good concordance with the Immunoscan RA ELISA test, Immunocap 250 and aCCP test on the Roche Modular systems.
The study found that including TSI in hyperthyroidism testing algorithms would reduce net diagnostic costs by up to 43%, reduce net costs of misdiagnosis and treatment of unexplained symptoms by up to 85%, and reduce time to diagnosis by up to 46%.
This multicenter clinical trial evaluated the performance of the IMMULITE® 2000 Anti-CCP IgG assay* (Siemens Healthcare Diagnostics) for reproducibility and clinical equivalence to the Axis-Shield Diagnostics DIASTAT Anti-CCP assay.
A multicenter clinical trial evaluated the IMMULITE® 2000 Anti-CCP IgG assay* performance for reproducibility and clinical equivalence to the Axis-Shield Diagnostics DIASTAT™ Anti-CCP assay using RA and non-RA diagnosed samples and control materials.
The objective of this study was to determine if the combination of the IMMULITE® 2000 Anti-CCP IgG*, Dimension Vista® RF, and Dimension Vista hsCRP or CRP assays improved the diagnostic sensitivity and specificity for RA diagnosis.
In this study, we evaluated the analytical and clinical performance of the newly developed automated chemiluminescent enzyme immunoassay* for measurement of CCP IgG levels in serum using the IMMULITE® 2000 analyzer.
The performance data indicate that the IMMULITE® 2000 Anti-CCP IgG assay is suitable to use as one parameter in the multicriterion classification of rheumatoid arthritis.
Overall, the IMMULITE® 2000 Anti-CCP IgG assay performed comparably to the Dimension Vista® RF assay for the diagnosis of rheumatoid arthritis, and in combination, the clinical sensitivity was improved from 79% (anti-CCP) and 83% (RF) to 93%.
The diagnosis of APS is based on the combined presence of typical clinical manifestations, e.g. a vascular thrombotic event or complications during pregnancy, as well as the presence of antibodies directed against phospholipid-binding proteins.
The IMMULITE® 2000 assay exhibited performance characteristics consistent with those of commercially available assays for the detection of anti-CCP IgG antibodies in clinically significant populations.
Anti–cyclic citrullinated peptide antibody (anti-CCP) measurements are valuable tools that can aid in the diagnosis of rheumatoid arthritis and predict the development of this disease
Levels of anti-CCP are predictive of the development of rheumatoid arthritis, are associated with disease severity and progression, and are more specific for diagnosis.